Clinical Report: Home OCT and Modeling May Reduce Trial Sizes
Overview
{'add': 'Specify how statistical power is maintained despite reduced sample size.'}
Background
{'add': 'Examples of traditional monitoring methods.'}
Data Highlights
{'format': 'Consider using bullet points for clarity.'}Key Findings
{'add': "Details on Monte Carlo simulations' implications."}Clinical Implications
{'expand': 'How home monitoring enhances patient engagement.'}
Conclusion
{'add': 'Challenges or limitations of home OCT implementation.'}
References
- Roche Researchers, Translational Vision Science & Technology, 2024 -- Home OCT and Modeling May Reduce Trial Sizes
- retinal physician — The Potential Impact of Home OCT on nAMD Management
- optometric management — A Different Perspective on an Age-Old Disease
- retinal physician — Early Insights Into Home OCT Monitoring Reveal Real-World Impact
- Retinal Physician — Data Presented at AAO Support Utility of Home OCT
- The Potential Impact of Home OCT on nAMD Management
- A Different Perspective on an Age-Old Disease
- Early Insights Into Home OCT Monitoring Reveal Real-World Impact
- Ophthalmology | Vol 132, Issue 4, Pages A1-A20, P1-P344, e1-e78, 375-506 (April 2025) | ScienceDirect.com by Elsevier
- Intravitreal Aflibercept 8 mg in Neovascular Age-Related Macular Degeneration: Ninety-Six-Week Results from the Randomized Phase 3 PULSAR Trial - ScienceDirect
- FDA Grants AI-Powered Notal Vision Home OCT "SCANLY" De Novo Marketing Authorization
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.







